Answers are grounded in this paper and cite their sources.
Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of SGLT2i on renal function and outcome remains uninvestigated. Methods We prospectively included 40 type 2 diabetic mellitus (T2DM) patients (median 68 years old, 29 male) who were hospitalized for decompensated HF and received SGLT2i during the index hospitalization. Of them, 24 patients had increases in estimated glomerular filtration rate (eGFR) at 12-month follow-up and 16 had decreases in eGFR. We investigated the factors associating with the improvement in renal function of SGLT2i therapy in participants. Results Lower plasma B-type natriuretic peptide (BNP) level and the use of renin-angiotensin system inhibitor (RASI) were independently associated with increases in eGFR during the follow-up period (p < 0.05 for both). Patients with both low plasma BNP levels and uses of RASI had significant increases in eGFR irrespective of the HbA1c levels. Conclusions Lower plasma BNP level and the use of RASI at baseline were associated with the renoprotective effect of SGLT2i among patients with decompensated HF and T2DM.
No takes yet. Share an insight, caveat, or question.
Nakagaito et al. (2021) studied this question.